Artemisinin is a drug used to treat multi-drug resistant strains of falciparum malaria. The compound (a sesquiterpene lactone) is isolated from the plant Artemisia annua. Not all plants of this species contain artemisinin.
One of the keys to quickly diagnosing anti-malarial drug resistance -- potentially saving lives -- lies in testing whole blood instead of extracting DNA, eliminating processing steps that can take hours or days.
Antimalarial drugs appear to follow a typical pattern, with early effectiveness eventually limited by the emergence of drug resistance.
Researchers have found that anti-malarial drug artemisinin could help patients with genetic or hereditary hearing loss. The study results were published in the latest issue of the journal Proceedings of the National Academy of Sciences (PNAS). The study was titled, “Unconventional secretory pathway activation restores hair cell mechanotransduction in an USH3A model.”
If a genetically or synthetically engineered organism is released into the environment, how will we know?
According to a new report from a United Nations Committee, antibiotic resistance levels are at an all time high and are the reason behind common infections becoming difficult to treat.
The powerful medicines known as artemisinins have plenty of mileage in them in the global fight against malaria, and concern about partial resistance has been overstated.
The medicinal powers of aspirin, digitalis, and the anti-malarial artemisinin all come from plants. A Salk Institute discovery of a potent neuroprotective and anti-inflammatory chemical in a native California shrub may lead to a treatment for Alzheimer's disease based on a compound found in nature.
Artemisinin is derived from the leaves and flowers of the annual mugwort (Artemisia annua) and has been used in traditional Chinese medicine for centuries. The effectiveness was investigated by the Chinese researcher Tu Youyou.
Currently, few antimalarial treatments exist that effectively kill liver-stage malaria parasites, which can lay dormant for months or years as in the case of Plasmodium vivax. Researchers from Kanazawa University have successfully demonstrated that administration of a baculovirus virion completely eliminates liver-stage parasites in a mouse model via BV-induced fast-acting innate immunity.
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.
A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.
A novel laboratory-synthesized molecule based in natural compounds found in marine gliding bacteria - known as marinoquinolines - is a strong candidate for the development of a new antimalarial drug.
Coupling free diagnostic tests for malaria with discounts on artemisinin combination therapy (ACT) when malaria is diagnosed can improve the rational use of ACTs and boost testing rates, according to a cluster-randomized trial published this week in PLOS Medicine by Wendy Prudhomme O’Meara of Duke University, USA, and colleagues.
Equal subsidies "surprisingly powerful," in promoting use of gold-standard medications, new study shows.
Research has revealed the shocking lack of access to essential medicines in India, despite thousands being approved in an attempt to generate wider availability.
Indiana University School of Medicine researchers have identified a way to block the ability of parasites that cause malaria to shield themselves against drug treatments in infected mice--a finding that could lead to the development of new approaches to combat this deadly disease in humans.
A new analysis of all relevant previously published clinical data shows how parasites causing malaria become resistant to a commonly used treatment for malaria in travellers.
The Global Health Innovative Technology Fund, a unique Japanese public-private partnership formed to battle infectious diseases around the globe, today announced US$16.7 million to support development of new compounds for fighting malaria and tuberculosis, a leishmaniasis vaccine and drug, and a treatment for a long-ignored flesh-eating infection.
The spread of a single multidrug resistant malaria parasite strain in Vietnam is cause for alarm say researchers.
Texas Biomedical Research Institute researchers, Dr. Tim Anderson and Dr. Ian Cheeseman, have partnered with researchers at the University of Notre Dame and the Center for Infectious Disease Research in Seattle to pursue studies in drug resistant malaria.